Comparative Pharmacology
Head-to-head clinical analysis: BROVANA versus DURAPHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROVANA versus DURAPHYL.
BROVANA vs DURAPHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Bronchodilator via beta-2 adrenergic receptor agonism; increases cAMP, relaxes bronchial smooth muscle.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Terminal elimination half-life is 7–9 hours in adults with normal hepatic function; prolonged to 20–30 hours in hepatic cirrhosis or heart failure. In neonates, half-life may exceed 30 hours due to immature CYP450 enzymes.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites. Less than 10% excreted unchanged in urine; approximately 70% recovered in urine as metabolites, 30% in feces.
Category C
Category C
Bronchodilator
Bronchodilator